Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China.
The Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China.
Clin Rheumatol. 2022 Jul;41(7):2213-2223. doi: 10.1007/s10067-022-06087-1. Epub 2022 Mar 30.
COVID-19 pandemic has already had a tremendous impact on the process of human society; the survival of mankind and the healthy living environment deterioration with the influence will last for many years. This meta-analysis aims to assess the risk of COVID-19 in patients with rheumatic diseases.
PubMed, Web of Science, Embase, China National Knowledge Infrastructure (CNKI), and Chinese Biomedical Database (CBM) were systematically searched with no language restriction up to July 5, 2021. The pooled rates were synthesized by fixed effect model or random effect model depending on heterogeneity.
A total of 83 articles were included in this meta-analysis. The incidence of COVID-19 in patient with rheumatic diseases was 0.0190 (95% CI: 0.0136-0.0252), and the hospitalization rate, intensive care unit admission rate, mechanical ventilation rate, and case fatality rate of patients with rheumatic diseases infected with COVID-19 were 0.4396 (95% CI: 0.3899-0.4898), 0.0635 (95% CI: 0.0453-0.0836), 0.0461 (95% CI: 0.0330-0.0609), and 0.0346 (95% CI: 0.0218-0.0493), respectively.
Our research shows that patients with rheumatic diseases have great risk of COVID-19. Differences in COVID-19 incidence, hospitalization rates, and mortality rates in regions were statistically significant. We still need to pay attention to the risk of COVID-19 in patients with rheumatic diseases.
• Although the risk of COVID-19 in patients with rheumatic diseases has been discussed in previous meta-analysis, their research directions were inconsistent, and few studies focus on prevalence or serious outcomes of COVID-19 in patient with rheumatic diseases, while the quality of these articles was variable. • The incidence of COVID-19 and serious clinical outcomes in patients with rheumatic diseases were still high along with differential risks in most regions. • The use of glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs did not affect the hospitalization rate and mortality in rheumatism patients with COVID-19.
新冠疫情已对人类社会进程产生巨大影响，人类的生存和健康的生活环境恶化将持续多年。本荟萃分析旨在评估风湿性疾病患者感染新冠病毒的风险。
系统检索了 PubMed、Web of Science、Embase、中国知网（CNKI）和中国生物医学文献数据库（CBM），无语言限制，检索截至 2021 年 7 月 5 日。根据异质性，采用固定效应模型或随机效应模型综合汇总率。
共纳入 83 篇文章。风湿性疾病患者感染新冠病毒的发病率为 0.0190（95%CI：0.0136-0.0252），风湿性疾病患者感染新冠病毒的住院率、重症监护病房入住率、机械通气率和病死率分别为 0.4396（95%CI：0.3899-0.4898）、0.0635（95%CI：0.0453-0.0836）、0.0461（95%CI：0.0330-0.0609）和 0.0346（95%CI：0.0218-0.0493）。
本研究表明风湿性疾病患者感染新冠病毒的风险较高。地区间新冠病毒发病率、住院率和死亡率的差异有统计学意义。我们仍需关注风湿性疾病患者感染新冠病毒的风险。
尽管之前的荟萃分析已经讨论了风湿性疾病患者感染新冠病毒的风险，但它们的研究方向不一致，很少有研究关注风湿性疾病患者感染新冠病毒的患病率或严重结局，而且这些文章的质量参差不齐。
风湿性疾病患者感染新冠病毒的发病率和严重临床结局仍然较高，且大多数地区存在差异风险。
风湿性疾病患者使用糖皮质激素和传统合成的疾病修饰抗风湿药物不会影响新冠病毒感染患者的住院率和死亡率。
Zotero 插件
